The Immunobiology of T Cell Therapies for Leukemias

Acta Haematologica

Volumn 96, Issue 4, 1996, Pages 189-213

  Shlomchik, Warren D ^a   Emerson, Stephen G ^a  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Allogeneic bone marrow transplantation; Alloimmunity; Chronic myelogenous leukemia; Graft versus host disease; Graft versus leukemia; GVHD; GVL; Lymphocyte infusions; Minor histocompatibility antigens

Indexed keywords

ANTILEUKEMIC AGENT; METHOTREXATE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ALLOGENIC BONE MARROW TRANSPLANTATION; ALLOIMMUNITY; BLOOD TOXICITY; CELLULAR IMMUNITY; CHRONIC MYELOID LEUKEMIA; HUMAN; IMMUNOBIOLOGY; IMMUNOTHERAPY; LEUKEMIA REMISSION; MONONUCLEAR CELL; NONHUMAN; PRIORITY JOURNAL; RELAPSE; REVIEW; T LYMPHOCYTE;

BONE MARROW TRANSPLANTATION; GRAFT VS HOST DISEASE; HUMANS; IMMUNITY, CELLULAR; LEUKEMIA; MAJOR HISTOCOMPATIBILITY COMPLEX; T-LYMPHOCYTES;

EID: 0029826799     PISSN: 00015792     EISSN: 14219662     Source Type: Journal    
DOI: 10.1159/000203786     Document Type: Article

References (144)

1. Champlin R: Allogeneic bone marrow transplantation using unrelated donors (review). Leuk Lymphoma 1993;2:149-152.
2. Schiller G, Gajewski J, Territo M, Nimer S, Lee M, Belin T, Champlin R: Long-term outcome of high-dose cytarabine-bascd consolidation chemotherapy for adults with acute myelogenous leukemia. Blood 1992;80:2977-2982.
3. Schiller G, Gajewski J, Nimer S, Territo M, Ho W, Lee M, Champlin R: A randomized study of intermediate versus conventional-dose cytara-bine as intensive induction for acute myelogenous leukaemia. Br J Haematol 1992;81:170- 177.
4. Schiller G, Gajewski J, Lee M, Ho W, Territo M, Champlin R: Benefit of high-dose cytara-bine-based consolidation chemotherapy for adults with acute myelogenous leukemia. Leuk Lymphoma 1994;15:85-90.
5. Petz LD: Development; in Blume KG, Petz LD (eds): Clinical Bone Marrow Transplantation. New York, Churchill Livingstone, 1983, pp 15-29.
6. Barnes DW, Corp MJ. Loutit JF, Neal FE: Treatment of murine leukaemia with X rays and homologous bone marrow. Br Med J 1956; 2:626-627.
7. Mathe G, Amiel JL, Schwarzenberg L, Cattan A, Schneider M: Adoptive immunotherapy of acute leukemia: Experimental and clinical results. Cancer Res 1965;25:1525-1531.
8. Horowitz MM. Gale RP, Sondel PM, Goldman JM, Kersey J, Kolb HJ, Rimrn AA, Ringdcn O, Rozman C, Speck B, Truitt RL, Zwaan FE, Bortin MM: Graft-versus-leukcmia reactions after bone marrow transplantation. Blood 1990;75:555-562.
9. Bar BM, Schattenberg A, Mensink EJ, Geurts Van Kessel A, Smctsers TF, Knops GH, Linders EH, De Witte T: Donor leukocyte infusions for chronic myeloid leukemia relapsed after allogeneic bone marrow transplantation. J Clin Oncol 1993;11:513-519.
10. Collins R, Wolff S, List A, Christiansen N, Pineiro L, Greer J, Goodman S, Dalton W, Gonzalez G, Herzig G, Phillips G, Fay J: Prospective multicenter trial of donor buffy coat infusion for relapsed hematologic malignancy post-allogeneic bone marrow transplantation (BMT). Blood 1994;84:333a.
11. Collins R, Shpilberg O, Drobyski W, Porter D, Antin J, Wolff S, Giralt S, Chetrit A, Ognoskie N, Prine S, Nemunaitis J: Donor leukocyte infusions (DLI) for post-bone marrow transplant (BMT) relapse: Retrospective cohort analysis of 141 cases. Blood 1995;86:563a.
12. Drobyski WR, Roth MS, Thibodeau SN, Gott-schall JL: Molecular remission occurring after donor leukocyte infusions for the treatment of relapsed chronic myelogenous leukemia after allogenic bone marrow transplantation. Bone Marrow Transplant 1992;10:301-304.
13. Drobyski WR, Keever CA, Roth MS, Koethe S, Hanson G, McFadden P. Gottschall JL, Ash RC, van Tuinen P, Horowitz MM, Flomenber N: Salvage immunotherapy using donor leukocyte infusions as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation: Efficacy and toxicity of a defined T-cell dose. Blood 1993;82:2310-2318.
14. Helg C, Roux E, Beris P, Cabrol C, Wacker P, Darbellay R, Wyss M, Jeannet M, Chapuis B, Roosnek E: Adoptive immunotherapy for recurrent CML after BMT. Bone Marrow Transplant 1993;12:125-129.
15. Hcrtenstein B. Wicsncth M, Novotny J. Bunjes D, Stefanie M. Heinze B. Hubner G, Heimpel H. Arnold R: Interferon-alpha and donor buffy coat transfusions for treatment of relapsed chronic myeloid leukemia after allogeneic bone marrow transplantation. Transplantation 1993;56:1114-1118.
16. Kolb HJ, Mittermullcr J, Clemm C, Holler E, Ledderose G, Brehm G. Heim M, Wilmanns W: Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 1990;76: 2462-2465.
17. Kolb HJ, Schattenberg A. Goldman JM. Her-tenstein B. Jacobsen N, Arcese W, Ljungman P. Ferrant A, Verdonck L, Niederwieser D. van Rhee F, Mittermueller J, dc Witte T, Holler E, Ansari H: Graft-vcrsus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia. Blood 1995;86:2041-2050.
18. Mackinnon S, Papadopoulos EB, Carabasi MH, Reich L, Collins NH, Boulad F, Castro-Malaspina H, Childs BH, Gillio AP. Keman NA, Small TN, Young JW, O’Reilly RJ: Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: Separation of graft-versus-leu-kemia responses from graft-versus-host disease. Blood 1995;86:1261-1268.
19. Porter DL, Roth MS, McGarigle C, Ferrara JL, Antin JH: Induction of graft-versus-host disease as immunotherapy for relapsed chronic myeloid leukemia. N Engl J Med 1994:330: 100-106.
20. van Rhee F, Lin F, Cullins JO, Spencer A, Cross NC, Chase A, Garicochea B. Bungey J, Barrett J, Goldman JM: Relapse of chronic myeloid leukemia after allogeneic bone marrow transplant: The case for giving donor leukocyte transfusions before the onset of hematologic relapse. Blood 1994;83:3377-3383.
21. Papadopoulos EB, Ladanyi M, Emanuel D, Mackinnon S, Boulad F, Carabasi MH, Castro-Malaspina H, Childs BH, Gillio AP, Small TN, Young JW, Keman NA, O’Reilly RJ: Infusions of donor leukocytes to treat Epstcin-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation. N Engl J Med 1994;330:1185-1191.
22. Tibcrghien P, Reynolds CW, Keller J, Spence S, Dcschaseaux M. Certoux JM, Contassot E. Murphy WJ, Lyons R, Chiang Y, Hcrvc P. I-ongo DL, Ruscetti FW: Ganciclovir treatment of herpes simplex thymidine kinase-transduced primary T lymphocytes: An approach for specific in vivo donor T-cell depletion after bone marrow transplantation? Blood 1994;84:1333-1341.
23. Tiberghien P: Use of suicide genes in gene therapy. J Leukoc Biol 1994;56:203-209.
24. Bonini C, Verzeletti S, Scrvida P, Rossini S, Traversari C, Ferrari G, Nobili N, Mavilio F, Bordignon C: Transfer of the HSV-TK gene into donor peripheral blood lymphocytes for in vivo immunomodulation of donor anti-tumor immunity after Allo-BMT. Blood 1994:84: 110a.
25. Sullivan KM. Deeg HJ. Sanders J, Klosterman A, Amos D, Shulman H, Sale G, Martin P, Witherspoon R, Appclbaum F, Doney K, Meyers SJ. McDonald GB, Weiden P. Fefer A, Buckner CD, Storb R. Thomas ED: Hyperacute graft-v-host disease in patients not given immunosuppression after allogeneic marrow transplantation. Blood 1986,67:1172-1175.
26. Sullivan KM, Storb R, Buckner CD, Fefer A, Fisher L, Weiden PL, Witherspoon RP, Appclbaum FR, Banaji M, Hansen J. et al: Graft-ver-sus-host disease as adoptive immunotherapy in patients with advanced hematologic neoplasms. N Engl J Med 1989;320:828-834.
27. Odom LF, August CS, Githens JH, Humbert JR, Morse H, Peakman D, Sharma B, Rusnak SL, Johnson FB: Remission of relapsed leukaemia during a graft-versus-host reaction: A ‘graft-versus-leukaemia reaction' in man? Lancet 1978;2:537-540.
28. Higano CS, Brixey M, Bryant EM, Dumam DM, Doney K, Sullivan KM, Singer JW: Durable complete remission of acute nonlymphocyt-ic leukemia associated with discontinuation of immunosuppression following relapse after allogeneic bone marrow transplantation: A case report of a probable graft-versus-lcukemia effect. Transplantation 1990;50:175-177.
29. Collins RH Jr., Rogers ZR, Bennett M, Kumar V, Nikein A, Fay JW: Hematologic relapse of chronic myelogenous leukemia following allogeneic bone marrow transplantation: Apparent graft-versus-leukemia effect following abrupt discontinuation of immunosuppression. Bone Marrow T ransplant 1992; 10:391 -395.
30. Giralt S, Hester J, Huh Y, Hirsch-Ginsber C, Rondon G. Seong D, Lee M, Gajewski J, Van Bcsicn K, Khouri I, Rakesha M, Przepiorka D, Korbling M, Talpaz M, Kantarjian H, Fischer H, Deisseroth A. Champlin R: CD8-depleted donor lymphocyte infusion as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation. Blood 1995;86:4337-4343.
31. Prentice HG, Sekhar M, Popat U, Deane M, Ray M. Steward B, Lawler M: Donor leukocyte infusions for relapsed acute leukemia post BMT. Blood 1995:86:566a.
32. Tricot G. Vesolc DH. Jagannath S, Hilton J, Munshi N, Barlogie B: Graft-versus-myeloma effect: Proof of principle. Blood 1996;87:1196- 1198.
33. Truitt RL, Atasoylu AA: Contribution of CD4+ and CD8+ T cells to graft-versus-host disease and graft-versus-leukemia reactivity after transplantation of MHC-compatiblc bone marrow. Bone Marrow Transplant 1991;8:51 -58.
34. Janeway C Jr, Bottomly K: Signals and signs for lymphocyte responses (review). Cell 1994; 76:275-285.
35. Nossal GJ: Negative selection of lymphocytes (review). Cell 1994;76:229-239.
36. Paul WE, Seder RA: Lymphocyte responses and cytokines. Cell 1994;76:241-251.
37. Springer TA: Traffic signals for lymphocyte recirculation and leukocyte emigration: The multistep paradigm (review). Cell 1994;76: 301-314.
38. Sprent J: T and B memory' cells (review). Cell 1994;76:315-322.
39. von Boehmer H: Positive selection of lymphocytes (review). Cell 1994;76:219-228.
40. Janeway CA, Travers P: Immunobiology: The Immune System in Health and Disease. London, Current Biology, 1994.
41. Germain RN: MHC-dependent antigen processing and peptide presentation: Providing ligands for T lymphocyte activation (review). Cell 1994;76:287-299.
42. Engelhard VH: Structure of peptides associated with MHC class I molecules. CurrOpin Immunol 1994;6:13-23.
43. Engelhard VH: Structure of peptides associated with class I and class II MHC molecules. Annu Rev Immunol 1994;12:181-207.
44. Wucherpfennig KW, Stromingcr JL: Selective binding of self peptides to disease-associated major histocompatibility complex (MHC) molecules: A mechanism for MHC-linkcd susceptibility to human autoimmune diseases (comment). J Exp Med 1995;181:1597-1601.
45. Gaczynska M, Rock KL, Goldberg AL: Role of protcasomes in antigen presentation. Enzyme Protein 1993:47:354-369.
46. Kovacsovics-Bankowski M, Rock KL: A pha-gosome-to-cytosol pathway for exogencous antigens presented on MHC class I molecules. Science 1995;267:243-246.
47. Jacobson S, Sekaly RP, Bellini WJ. Johnson CL, McFarland HF, Long EO: Recognition of intracellular measles virus antigens by HLA class II restricted measles virus-specific cytotoxic T lymphocytes. Ann NY Acad Sei 1988: 540:352-353.
48. Jacobson S, Sekaly RP, Jacobson CL. McFarland HF, Long EO: HLA class II-restricted presentation of cytoplasmic measles virus antigens to cytotoxic T cells. J Virol 1989:63:1756-1762.
49. Jaraqucmada D, Marti M, Long EO: An endogenous processing pathway in vaccinia virus-infected cells for presentation of cytoplasmic antigens to class II-restricted T cells. J Exp Med 1990;172:947-954.
50. Sekaly RP, Jacobson S, Richert JR, Tonneley C. McFarland HF, Long EO: Antigen presentation to HLA class II-restricted measles virus-specific T-cell clones can occur in the absence of the invariant chain. Proc Natl Acad Sei USA 1988;85:1209-1212.
51. Rudd CE, Janssen O, Cai YC. da Silva AJ. Raab M, Prasad KV: Two-step TOR zeta/CD3-CD4 and CD28 signaling in T cells: SH2/SH3 domains, protein-tyrosinc and lipid kinases. Immunol Today 1994;15:225-234.
52. Weiss A: T cell antigen receptor signal transduction: A tale of tails and cytoplasmic protein-tyrosine kinases (review). Cell 1993;73:209-212.
53. Weiss A, Littman DR: Signal transduction by lymphocyte antigen receptors (review). Cell 1994;76:263-274.
54. Guinan EC. Gribben JG. Boussiotis VA, Freeman GJ, Nadler LM: Pivotal role of the B7:CD28 pathway in transplantation tolerance and tumor immunity (review). Blood 1994;84: 3261-3282.
55. June CH, Blucstone JA, Nadler LM, Thompson CB: The B7 and CD28 receptor families (review). Immunol Today 1994;15:321-331.
56. Boussiotis VA, Freeman GJ, Gray G. Gribben J, Nadler LM: B7 but not intercellular adhesion molecule-1 costimulation prevents the induction of human alloantigen-specific tolerance. J Exp Med 1993;178:1753-1763.
57. Boussiotis VA, Gribben JG, Freeman GJ. Nadler LM: Blockade of the CD28 costimulatory pathway: A means to induce tolerance (review). Curr Opin Immunol 1994;6:797-807.
58. Boussiotis VA, Barber DL, Nakarai T, Freeman GJ, Gribben JG, Bernstein GM, D’An-drea AD, Ritz J, Nadler LM: Prevention of T cell ancrgy by signaling through the gamma c chain of the 11-2 receptor. Science 1994;266: 1039-1042.
59. Gimmi CD, Freeman GJ. Gribben JG, Gray G, Nadler LM: Human T-cell clonal anergy is induced by antigen presentation in the absence of B7 costimulation. Proc Natl Acad Sei USA 1993;90:6586-6590.
60. Robey E. Fowlkes BJ: Selective events in T cell development (review). Annu Rev Immunol 1994;12:675-705.
61. Fowlkes BJ, Ramsdcll F: T-cell tolerance (review). Curr Opin Immunol 1993;5:873-879.
62. Berkc G: Unlocking the secrets of CTL and NK cells. Immunol Today 1995;16:343-346.
63. Berke G: The CTL’s kiss of death. Cell 1995; 81:9-12.
64. Stalder T, Hahn S, Erb P: Fas antigen is the major target molecule for CD4+ T cell-mediated cytotoxicity. J Immunol 1994; 152: 1127-1133.
65. Wang ZQ. Dudhane A, Orlikowsky T, Clarke K, Li X, Darzynkicwicz Z, Hoffmann MK: CD4 engagement induces Fas antigen-dependent apoptosis of T cells in vivo. Eur J Immunol 1994;24:1549-1552.
66. Nagata S, Golstein P: The Fas death factor (review). Science 1995;267:1449-1456. cl-Khatib M, Stanger BZ, Dogan H, Cui H, Ju ST: The molecular mechanism of FasL-me-diated cytotoxicity by CD4+ Th 1 clones. Cell Immunol 1995;163:237-244.
67. Simpson E: Minor histocompatibility antigens (review). Immunol Lett 1991;29:9-14.
68. Roopenian DC, Christianson GJ, Davis AP, Zuberi AR, Mobraaten LE: The genetic origin of minor histocompatibility antigens. Immuno-genetics 1993;38:131-140.
69. Bevan MJ: Antigen presentation to cytotoxic T lymphocytes in vivo. J Exp Med 1995,182: 639-641.
70. Reis c, Sousa C, Germain RN: Major histocompatibility complex class I presentation of peptides derived from soluble exogenous antigen by a subset of cells engaged in phagocytosis. J Exp Med 1995;182:841-851.
71. Udono H, Srivastava PK: Heat shock protein 70-associated peptides elicit specific cancer immunity. J Exp Med 1993;178:1391-1396.
72. Suto R, Srivastava PK: A mechanism for the specific immunogenicity of heat shock protein-chaperoned peptides. Science 1995;269:158-1588.
73. Rock KL, Rothstein L, Gamble S, Flcischacker C: Characterization of antigen-presenting cells that present exogenous antigens in association with class I MHC molecules. J Immunol 1993; 150:438-446.
74. Kovacsovics-Bankowski M, Rock KL: Presentation of exogenous antigens by macrophages: Analysis of major histocompatibility complex class I and II presentation and regulation by cytokines. Eur J Immunol 1994:24:2421-2428.
75. Pati AR, Godder K, Abhyankar S, Parrish R. Lamb L, Gee AP, Henslee-Downey PJ: Preemptive donor leukocyte infusions to prevent relapse in patients with high risk hematological malignancies undergoing bone marrow tranplant using partially mismatched related donors. Blood 1995;86:564a.
76. Komgold R, Sprent J: T-cell subsets and graft-vs.-host disease; in Burakoff SJ, Deeg HJ, Ferrara J. Atkinson K (eds): Graft-vs.-Host Disease. New York, Dckker, 1990, vol 12, pp 31-50.
77. Aizawa S, SadoT: Graft-versus-Ieukemia effect in MHC-compatible and incompatible allogeneic bone marrow transplantation of radiation-induced, leukemia-bearing mice. Transplantation 1991;52:885-889.
78. Okunewick JP, Kociban JP, Machen LL, Buffo MJ: The role of CD4 and CD8 T cells in graft-vcrsus-leukemia response in Rauscher murine leukemia. BMT 1991;8:445-452.
79. Sykes M, Abraham VS, Harty MW, Pearson DA: 11-2 reduces graft-vcrsus-host disease and preserves a graft-versus-leukcmia effect by selectively inhibiting CD4+ T cell activity. J Immunol 1993;150:197-205.
80. Sykes M, Harty MW, Szot GL. Pearson DA: Interleukin-2 inhibits graf-vcrsus-host disease-promoting activity of CD4+ cells while preserving CD4- and CD8-mcdiatcd graft-versus-leukemia effects. Blood 1994;83:2560-2569.
81. Nicdcrwieser D, Grassegger A, Aubock J. Herald M, Nachbaur D, Rosenmayr A, Gachter A, Nussbaumer W, Gaggl S, Ritter M, Huber C: Correlation of minor histocompatibility antigen-specific cytotoxic T lymphocytes with graft-versus-host disease status and analyses of tissue distribution of their target antigens. Blood 1993;81:2200-2208.
82. Nishimura M, Akaza T, Mitomi Y, Nieda M, Minami M, Juji T: Establishment of human minor histocompatibility antigen-specific cytotoxic T cell clones restricted by HLA-DR9. T ransplantation 1993;55:1181 -1186.
83. Faber LM, van Luxemburg-Hcijs SA, Wil-lemze R. Falkenburg JH: Generation of leukemia-reactive cytotoxic T lymphocyte clones from the HLA-idcntical bone marrow donor of a patient with leukemia. J Exp Med 1992; 176: 1283-1289.
84. van Els CA, D’Amaro J, Pool J, Blokland E, Bakker A, van Elsen PJ, van Rood JJ, Goulmy E: Immunogenetics of human minor histocompatibility antigens: Their polymorphism and immunodominance. Immunogenetics 1992,35: 161-165.
85. Marijt WA, Veenhof WF. Goulmy E. Willemze R, van Rood JJ, Falkenburg JH: Minor histocompatibility antigens HA-1-, -2-, and -4-, and HY-spccific cytotoxic T-cell clones inhibit human hematopoietic progenitor cell growth by a mechanism that is dependent on direct cell-cell contact. Blood 1993;82:3778-3785.
86. Goulmy E: Minor histocompatibility antigens in man and their role in transplantation; in Morris PJ; Tilney MD (eds): Transplantation Reviews, Philadelphia, Saunders, 1988, vol 2, pp 29-54.
87. Marijt WA, Vcenhof WF, Brand A. Goulmy E, Fibbe WE, Willemze R, van Rood JJ, Falkcn-burg JH: Minor histocompatibility antigen-specific cytotoxic T cell lines, capable of lysing human hematopoietic progenitor cells, can be generated in vitro by stimulation with HLA-identical bone marrow cells. J Exp Med 1991; 173:101-109.
88. dc Bucger M, Bakker A, Van Rood JJ, Van der Woucc F, Goulmy E: Tissue distribution of human minor histocompatibility antigens: Ubiquitous versus restricted tissue distribution indicates heterogeneity among human cytotoxic T lymphocyte-defined non-MHC antigens. J Immunol 1992:149:1788-1794.
89. De Bueger M, Bakker A. Van Rood JJ, Goulmy E: Minor histocompatibility antigens, defined by graft-vs.-host disease-derived cytotoxic T lymphocytes, show variable expression on human skin cells. Eur J Immunol 1991:21:2839-2844.
90. Schreuder GM. Pool J. Blokland E, van Els C, Bakker A, van Rood JJ, Goulmy E: A genetic analysis of human minor histocompatibility antigens demonstrates Mendelian segregation independent of HLA. Immunogenetics 1993; 38:98-105.
91. de Haan JM, Sherman NE, Blokland E, Hucz-ko E, Koning F, Drijfhout JW. Skipper J, Sha-banowitz J, Hunt DF, Engelhard VH. Goulmy E: Identification of graft versus host disease-associated human minor histocompatibility antigen. Science 1995;268:1476-1480.
92. Wang W, Meadows LR, den Haan JM, Sherman NE, Chen Y, Blokland E, Shabanowitz J. Agulnik AI, Hendrickson RC, Bishop CE, Hunt DF, Goulmy E, Engelhard, VH: Human H-Y: A male-specific histocompatibility antigen derived from the SMCY protein. Science 1995;269:1588-1590.
93. Scott DM, Ehrmann IE, Ellis PS. Bishop CE, Agulnik AI, Simpson E, Mitchell MJ: Identification of a mouse malc-spccific transplantation antigen, H-Y. Nature 1995;376:695-698.
94. Faber LM. van Luxemburg-Heijs SA, Veen-hof WF, Willemze R, Falkenburg JH: Generation of CD4+ cytotoxic T-lymphocyte clones from a patient with severe graft-versus-host disease after allogeneic bone marrow transplantation: Implications for graft-versus-leu-kemia reactivity. Blood 1995:86:2821-2828.
95. Faber LM, van der Hoeven J, Goulmy E, Hooftman-den Otter AL, van Luxemburg-Heijs SA, Willemze R, Falkenburg JH: Recognition of clonogenic leukemic cells, remission bone marrow and HLA-idcntical donor bone marrow by CD8+ or CD4+ minor histocompatibility antigen-specific cytotoxic T lymphocytes. J Clin Invest 1995;96:877-883.
96. Truitt RJ, LeFever AV, Shih CC, Jeske JM, Martin TM: Graft-vs.-leukemia effect; in Bu-rakoff SJ. Deeg HJ, Ferrara J. Atkinson K (eds): Graft-vs.-Host Disease. New York, Dckker, 1990, vol 12, pp 17-204.
97. Goulmy E, Schipper R, Pool J, Blokland E, Falkenburg JHF, Vossen J, Gratwohl A, Vogelsang G, van Houwelingen HD, van Rood JJ: Mismatches of Minor histocompatibility antigens between HLA-identical donors and recipients and the development of graft-versus-host disease after bone marrow transplantation. N Engl J Med 1996;334:281-285.
98. Brochu S, Baron C, Hctu F, Roy DC, Perreault C: Oligoclonal expansion of CTLs directed against a restricted number of dominant minor histocompatibility antigens in hemopoietic chimeras. J Immunol 1995; 155: 5104-5114.
99. Wolpert E, Franksson L, Karre K: Dominant and cryptic antigens in the MHC class I restricted T cell response across a complex minor histocompatibility barrier: Analysis and mapping by elution of cellular peptides. Int Immunol 1995;7:919-928.
100. Wettstein PJ, Bailey DW: Immunodomi-nance in the immune response to ‘multiple' histocompatibility antigens. Immunogenetics 1982;16:47-58.
101. von Herrath MG, Dockter J, Nerenbcrg M, Gairin JE, Oldstone MB: Thymic selection and adaptability of cytotoxic T lymphocyte responses in transgenic mice expressing a viral protein in the thymus. J Exp Med 1994; 180:1901-1910.
102. Hunt DF, Henderson RA, Shabanowitz J. Sa-kaguchi K, Michel H, Sevilir N, Cox AL, Appella E, Engelhard VH: Characterization of peptides bound to the class I MHC molecule HLA-A2.1 by mass spectrometry. Science 1992;255:1261-1263.
103. Yin L, Poirier G, Neth O, Hsuan JJ, Totty NF, Stauss HJ: Few peptides dominate cytotoxic T lymphocyte responses to single and multiple minor histocompatibility antigens. Int Immunol 1993;5:1003-1009.
104. Pion S, Fontaine P, Baron C, Gyger M, Perreault C: Immunodominant minor histocompatibility antigens expressed by mouse leukemic cells can serve as effective targets for T cell immunotherapy. J Clin Invest 1995;95: 1561-1568.
105. Miller SD, McRae BL. Vanderlugt CL, Nikcc-vich KM, Pope JG, Pope L, Karpus WJ: Evolution of the T-cell repertoire during the course of experimental immune-mediated de-myelinating diseases. Immunol Rev 1995; 144:225-244.
106. Lehmann PV, Sercarz EE, Forsthuber T, Dayan CM, Gammon G: Determinant spreading and the dynamics of the autoimmune T-cell repertoire. Immunol Today 1993;14:203-208.
107. McRae BL, Miller SD: Fine specificity of CD4+ T cell responses to the dominant ence-phalitogenic PLP 139-151 peptide in SJL/J mice. Neurochem Res 1994:19:997-1004.
108. Mor F, Cohen IR: Shifts in the epitopes of myelin basic protein recognized by Lewis rat T cells before, during, and after the induction of experimental autoimmune encephalomyelitis. J Clin Invest 1993;92:2199-2206.
109. McRae BL. Kennedy MK, Tan LJ, Dal Canto MC, Picha KS, Miller SD: Induction of active and adoptive relapsing experimental autoimmune encephalomyelitis (EAE) using an ence-phalitogenic epitope of proteolipid protein. J Ncuroimmunol 1992;38:229-240.
110. Mokhtarian F, McFarlin DE, Raine CS: Adoptive transfer of myelin basic protein-sensitized T cells produces chronic relapsing demyelinating disease in mice. Nature 1984; 309:356-358.
111. McRae BL, Vanderlugt CL, Dal Canto MC, Miller SD: Functional evidence for epitope spreading in the relapsing pathology of experimental autoimmune encephalomyelitis. J Exp Med 1995;182:75-85.
112. Vandenbark AA, Vainiene M, Celnik B, Ha-shim GA, Buenafe A, Offner H: Definition of encephalitogenic and immunodominant epitopes of guinea pig myelin basic protein (Gp-BP) in Lewis rats tolerized neonatally with Gp-BP or Gp-BP peptides. J Immunol 1994: 153:852-861.
113. Schultz KR. Paquet J, Bader S, HayGlass KT: Requirement for B cells in T cell priming to minor histocompatibility antigens and development of graft-versus-host disease. Bone Marrow Transplant 1995; 16:289-295.
114. Liblau RS, Singer SM, McDevitt HO: Thl and Th2 CD4+ T cells in the pathogenesis of organ-specific autoimmune diseases. Immunol Today 1995;16:34-38.
115. Dranoff G, Jaffee E, Lazenby A, Golumbek P, Levitsky H, Brose K, Jackson V, Hamada H, Pardoll D, Mulligan RC: Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Nat Acad Sei USA 1993;90:3539-3543.
116. Dranoff G, Mulligan RC: Gene transfer as cancer therapy (review). Adv Immunol 1995; 58:417-454.
117. Hock H, Dorsch M, Richter G, Kunzendorf U, Kruger-Krasagakes S, Blankenstein T, Qin Z, Diamantstein T: Tumor-cell-targeted cytokine gene transfer in experimental models for cancer therapy (review). Nat Immun 1994; 13: 85-92.
118. van der Harst D. Goulmy E, Falkenburg JH. Kooij-Winkelaar YM. van Luxemburg-Heijs SA, Goselink HM, Brand A: Recognition of minor histocompatibility antigens on lymphocytic and myeloid leukemic cells by cytotoxic T-ccll clones. Blood 1994:83:1060-1066.
119. Fisher GH. Rosenberg FJ. Straus SE, Dale JK. Middleton LA. Lin AY, Strober W, Le-nardo MJ, Puck JM: Dominant interfering Fas gene mutations impair apoptosis in a human autoimmune lymphoproliferative syndrome. Cell 1995;81:935-946.
120. Nagata S: Mutations in the Fas antigen gene in Ipr mice (review). Semin Immunol 1994;6: 3-8.
121. Cascino I, Papoff G, De Maria R, Testi R, Ruberti G: Fas/Apo-1 (CD95) receptor lacking the intracytoplasmic signaling domain protects tumor cells from Fas-mediatcd apoptosis. J Immunol 1996:156:13-17.
122. Hollander GA. Widmer B. Burakoff SJ: Loss of normal thymic repertoire selection and persistence of autoreactive T cells in graft vs host disease. J Immunol 1994; 152:1609-1617.
123. Khouri I, Keating MJ. Przepiorka D. van Besien K, Gajewski J, O’Brien S, Huh YO, Mehra R, Giralt S, Seong D, Korbling M, Deisseroth AB. Champlin RE: Stem cell transplantation for chronic lymphocytic leukemia: Graft-vcrsus-leukemia without acute graft-versus-host-disease. Blood 1995:86: 457a.
124. Schreiber H: Tumor immunology; in Paul WE (ed): Fundamental Immunology, ed 3. New York, Raven Press, 1993. pp 1143-1178.
125. Ward PL, Koeppen HK, Hurtcau T, Rowley DA, Schreiber H: Major histocompatibility complex class I and unique antigen expression by murine tumors that escaped from CD8+ T-cell-depcndcnt surveillance. Cancer Res 1990;50:3851-3858.
126. Ward PL. Koeppen H, Hurtcau T, Schreiber H: Tumor antigens defined by cloned immunological probes are highly polymorphic and are not detected on autologous normal cells. J Exp Med 1989;170:217-232.
127. Wortzel RD. Urban JL, Philipps C, Fitch FW, Schreiber H: Independent immunodominant and immunoreccssive tumor-specific antigens on a malignant tumor: Antigenic dissection with cytolytic T cell clones. J Immunol 1983;130:2461-2466.
128. Ward PL, Schreiber H: MHC class I restricted T cells and immune surveillance against transplanted ultraviolet light-induced tumors. Semin Cancer Biol 1991;2:32-328.
129. Wortzel RD, Urban JL, Schreiber H: Malignant growth in the normal host after variant selection in vitro with cytolytic T-cell lines. Proc Natl Acad Sei USA 1984,81:2186-2190.
130. Martin PJ, Keman NA: T-ccll depletion for the prevention of graft-vs.-host disease; in Bu-rakoif SJ, Deeg HJ, Ferrara J, Atkinson K (eds): Graft-vs.-Host Disease. New York, Dekker, 1990, vol 12.
131. Ferrara JL: Paradigm shift for graft-versus-host disease (editorial). Bone Marrow transplant 1994;14:183-184.
132. Ferrara JL: Cytokine dysregulation as a mechanism of graft versus host disease (review). Curr Opin Immunol 1993;5:794-799.
133. Ferrara JL, Abhyankar S, Gilliland DG: Cytokine storm of graft-versus-host disease: A critical effector role for interleukin-1. Transplant Proc 1993;25:1216-1217.
134. Tough DF. Sprent J: Life span of naive and memory T cells. Stem Cells 1995; 13:242-249.
135. Tough DF, Sprent J: Lifespan of lymphocytes. Immunol Res 1995;14:1-12.
136. Sprent J, Tough DF: Lymphocyte life-span and memory. Science 1994;265:1395-1400.
137. Sprent J: Lifespans of naive, memory and effector lymphocytes. Curr Opin Immunol 1993;5:433-438.
138. Miller DG, Adam MA, Miller AD: Gene transfer by retrovirus vectors occurs only in cells that are actively replicating at the time of infection. Mol Cell Biol 1990;10:4239-4242.
139. Walter EA, Greenberg PD, Gilbert MJ, Finch RJ, Watanabc KS, Thomas ED, Riddell SR: Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N Engl J Med 1995;333:1038-1044.
140. Riddell SR, Walter BA, Gilbert MJ, Greenberg PD: Selective reconstitution of CD8+ cytotoxic T lymphocyte responses in immu-nodeficient bone marrow transplant recipients by the adoptive transfer of T cell clones. Bone Marrow Transplant 1994; 14:S78-84.
141. Falo LD Jr, Kovacsovics-Bankowski M, Thompson K, Rock KL: Targeting antigen into the phagocytic pathway in vivo induces protective tumour immunity. Nature Med 1995;1:649-653.
142. Kovacsovics-Bankowski M, Clark K, Bena-cerraf B, Rock KL: Efficient major histocompatibility complex class I presentation of exogenous antigen upon phagocytosis by macrophages. Proc Natl Acad Sci USA 1993,90: 4942-4946.
143. Pardoll DM: New strategies for enhancing the immunogenicity of tumors. Curr Opin Immunol 1993;5:719-725.
144. Banchereau J, Bazan F, Blanchard D, Briere F, Galizzi JP, van Kooten C, Liu YJ, Rousset F, Saeland S: The CD40 antigen and its ligand (review). Annu Rev Immunol 1994; 12:881-922.